Form 4 for TXG 10x Genomics, Inc.
Accepted 2025-02-25 00:00:00 ET · period of report 2025-02-21 · accession 0001610717-25-000034 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-25 | 2025-02-21 | TXG | MATEO ALAN | Dir | P - Purchase | $11.14 | +40.0K | 61.7K | +184% | +$445.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2025-02-21 | P | A | 40,000 | $11.14 | 61,691 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $11.04 to $11.2751. The price reported above reflects the weighted average purchase price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate sale price. |